Novo Nordisk’s Wegovy Survey Impacts Eli Lilly Shares Amid Weight Loss Drug Competition

Novo Nordisk's latest U.S. survey reveals that 46% of Wegovy users experienced reduced 'food noise,' a mental preoccupation with food that hinders weight loss efforts. The Danish pharmaceutical giant also reported improved mental well-being among participants, though sample size details remain undisclosed.

Market reaction was immediate, with Eli Lilly's shares dipping nearly 1% following the announcement. This compounds pressure on competitors after Novo Nordisk's previous disclosure of Wegovy's 19% weight loss efficacy at triple dosage.

The findings, presented at the European Association for the Study of Diabetes conference, showed food noise prevalence dropping from 60% to 20% post-treatment. While the data strengthens Wegovy's clinical profile, analysts note the weight loss drug market remains fiercely contested.